To the Editor: Solomon et al. (Sept. 22 issue)(1) report on the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial, which showed reduced risks of heart failure-related outcomes (hospitalization for heart failure or an urgent visit for heart failure) among patients with a mildly reduced or preserved left ventricular ejection fraction who received dapagliflozin. These findings are likely to be included in guidelines and shape clinical practice shortly. One interesting aspect of the trial was confirmation that dapagliflozin was effective in patients with a left ventricular ejection fraction of 60% or more . . .
Gabrielli, D., Oliva, F., Zuccala', G., Dapagliflozin in Heart Failure with Preserved Ejection Fraction, <<THE NEW ENGLAND JOURNAL OF MEDICINE>>, 2023; 388 (3): 286-288. [doi:10.1056/nejmc2213974] [https://hdl.handle.net/10807/326703]
Dapagliflozin in Heart Failure with Preserved Ejection Fraction
Zuccala', Giuseppe
2023
Abstract
To the Editor: Solomon et al. (Sept. 22 issue)(1) report on the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial, which showed reduced risks of heart failure-related outcomes (hospitalization for heart failure or an urgent visit for heart failure) among patients with a mildly reduced or preserved left ventricular ejection fraction who received dapagliflozin. These findings are likely to be included in guidelines and shape clinical practice shortly. One interesting aspect of the trial was confirmation that dapagliflozin was effective in patients with a left ventricular ejection fraction of 60% or more . . .
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
